REFERENCES

1. Kroop IG, Shackman NH. Level of C-reactive protein as a measure of acute myocardial infarction. Proc Soc Exp Biol Med 1954;86:95-7.

2. Pepys MB, Baltz ML. Acute phase proteins with special reference to C-reactive protein and related proteins (pentraxins) and serum amyloid A protein. Adv Immunol 1983;34:141-212.

3. Andreotti F, Roncaglioni MC, Hackett DR, et al. Early coronary reperfusion blunts the procoagulant response of plasminogen activator inhibitor-1 and von Willebrand factor in acute myocardial infarction. J Am Coll Cardiol 1990;16:1553-60.

4. Meade TW, Mellows S, Brozovic M, et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986;2:533-7.

5. Kannel WB. Fibrinogen and risk of cardiovascular disease: the framingham study. JAMA 1987;258:1183.

6. Yarnell JW, Baker IA, Sweetnam PM, et al. Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease. The Caerphilly and Speedwell collaborative heart disease studies. Circulation 1991;83:836-44.

7. Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 1994;331:417-24.

8. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999;340:115-26.

9. Bermudez EA, Rifai N, Buring J, Manson JE, Ridker PM. Interrelationships among circulating interleukin-6, C-reactive protein, and traditional cardiovascular risk factors in women. Arterioscler Thromb Vasc Biol 2002;22:1668-73.

10. Kohchi K, Takebayashi S, Hiroki T, Nobuyoshi M. Significance of adventitial inflammation of the coronary artery in patients with unstable angina: results at autopsy. Circulation 1985;71:709-16.

11. Crea F, Andreotti F. The unstable plaque: a broken balance. Eur Heart J 2009;30:1821-3.

12. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685-95.

13. Libby P, Ridker PM, Hansson GK; Leducq Transatlantic Network on Atherothrombosis. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 2009;54:2129-38.

14. Morton AC, Rothman AM, Greenwood JP, et al. The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart Study. Eur Heart J 2015;36:377-84.

15. Ridker PM, Everett BM, Thuren T, et al; CANTOS Trial Group. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 2017;377:1119-31.

16. Ridker PM, Everett BM, Pradhan A, et al; CIRT Investigators. Low-dose methotrexate for the prevention of atherosclerotic events. N Engl J Med 2019;380:752-62.

17. Tardif JC, Kouz S, Waters DD, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med 2019;381:2497-505.

18. Nidorf SM, Fiolet ATL, Mosterd A, et al; LoDoCo2 Trial Investigators. Colchicine in Patients with Chronic Coronary Disease. N Engl J Med 2020;383:1838-47.

19. Buckley LF, Abbate A. Interleukin-1 blockade in cardiovascular diseases: a clinical update. Eur Heart J 2018;39:2063-9.

20. Mailer RK, Joly AL, Liu S, Elias S, Tegner J, Andersson J. IL-1β promotes Th17 differentiation by inducing alternative splicing of FOXP3. Sci Rep 2015;5:14674.

21. Dalbeth N, Lauterio TJ, Wolfe HR. Mechanism of action of colchicine in the treatment of gout. Clin Ther 2014;36:1465-79.

22. El Hasbani G, Jawad A, Uthman I. Colchicine: An ancient drug with multiple benefits. Curr Pharm Des 2020; doi: 10.2174/1381612826666201023144320.

23. Yang M, Lv H, Liu Q, et al. Colchicine alleviates cholesterol crystal-induced endothelial cell pyroptosis through activating AMPK/SIRT1 pathway. Oxid Med Cell Longev 2020;2020:9173530.

24. Cirillo P, Taglialatela V, Pellegrino G, et al. Effects of colchicine on platelet aggregation in patients on dual antiplatelet therapy with aspirin and clopidogrel. J Thromb Thrombolysis 2020;50:468-72.

25. Cimmino G, Conte S, Morello A, et al. Colchicine inhibits the prothrombotic effects of oxLDL in human endothelial cells. Vascul Pharmacol 2020:106822.

26. Pratt J, Roux M, Henneguelle E, Stutzmann JM, Laduron PM. Neuroprotective effects of colchicine in the gerbil model of cerebral ischaemia. Neurosci Lett 1994;169:114-8.

27. Bedoui Y, Guillot X, Sélambarom J, et al. Methotrexate an old drug with new tricks. Int J Mol Sci 2019;20:5023.

28. Ziff OJ, Samra M, Howard JP, et al. Beta-blocker efficacy across different cardiovascular indications: an umbrella review and meta-analytic assessment. BMC Med 2020;18:103.

29. Bangalore S, Makani H, Radford M, et al. Clinical outcomes with β-blockers for myocardial infarction: a meta-analysis of randomized trials. Am J Med 2014;127:939-53.

30. ClinicalTrails.Gov. Available from: https://www.clinicaltrials.gov/ct2/results?term=coronary+disease&cond=Inflammation&age_v=&gndr=&type=Intr&rslt=&Search=Apply [Last accessed on 15 Nov 2020].

31. CONVINCE Trial. Available from: https://clinicaltrials.gov/ct2/show/NCT02898610 [Last accessed on 15 Nov 2020].

32. Chinese study. Available from: https://clinicaltrials.gov/ct2/show/NCT02035891 [Last accessed on 15 Nov 2020].

33. COLCOVID Trial. Available from: https://clinicaltrials.gov/ct2/show/NCT04328480 [Last accessed on 15 Nov 2020].

34. COLCORONA Trial. Available from: https://clinicaltrials.gov/ct2/show/NCT04322682 [Last accessed on 15 Nov 2020].

35. Imazio M, Brucato A, Cemin R, et al; ICAP Investigators. A randomized trial of colchicine for acute pericarditis. N Engl J Med 2013;369:1522-8.